Trial Profile
A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of Two Intramuscular Doses of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine Containing Respiratory Syncytial Virus (RSV) SHe Antigen and a Novel Adjuvant DepoVaxTM, or SHe A Antigen Co-administered With Aluminum Hydroxide, or Placebo to Healthy Adults ≥50-64 Years of Age
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs DPX RSV (Primary) ; Alum
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
- 30 Mar 2018 Results assessing safety and immunogenicity published in the Journal of Infectious Diseases
- 22 Feb 2018 Planned End Date changed from 1 Jun 2017 to 1 Jul 2019.